Select Sidearea

Populate the sidearea with useful widgets. It’s simple to add images, categories, latest post, social media icon links, tag clouds, and more.

hello@youremail.com
+1234567890

News Archive

SFA THERAPEUTICS, INC. ANNOUNCES START OF PHASE 1b CLINICAL TRIAL IN THE TREATMENT OF MILD-TO-MODERATE PLAQUE PSORIASIS

JENKINTOWN, PA, UNITED STATES, April 8, 2021 /EINPresswire.com/ — SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start…

SFA THERAPEUTICS INVITED TO PRESENT AT ANGEL VENTURE FAIR

Investors Meet Thirty of Top Startups in America-Angel Venture TUE, OCT 13 2020 9:00 AM—FRI, OCT 30 2020 4:00 PM SFA Therapeutics has been selected to present…

SFA Therapeutics Accepted To The Y-Combinator Accelerator Summer Cohort 2021

SFA Therapeutics was accepted into the highly competitive summer Y-Combinator Summer Cohort. Y-Combinator  is an American seed money startup accelerator launched…

2021 Most Fundable Company

Read More

Pismo Ventures’ National Venture Plan Startup Competition Announces Winners

EcoSoul Home and SFA Therapeutics (1st place tie,) Read More

SFA THERAPEUTICS, INC. CLOSES SEED ROUND RAISE of $4M

Funds are focused on Phase 1b clinical trial in psoriasis Read More

SFA Publishes new approach to treating Hepatitis B and Chronic Liver Disease, with the the goal of developing a functional cure

Abstract Patients who are carriers of the hepatitis B virus (HBV) are at high risk of chronic liver disease (CLD) which…

SFA Therapeutics to Present at Biotech Showcase, San Francisco, CA

BIOTECH SHOWCASE: THE INVESTOR CONFERENCE FOR INNOVATORS Ira Spector, CEO of SFA Therapeutics will be presenting a corporate update at the…

SFA Therapeutics CEO Quoted in the Wall Street Journal Article on Biotech Fundraising

Tales From the 2022 Biotech VC Fundraising Trail After the bonanza of 2021, life-sciences entrepreneurs reset their expectations as financing contracted…

SFA Therapeutics Announces FDA IND Approval To Begin NASH Trial

SFA Therapeutics will begin testing of SFA001 in a Phase 1 exploratory trial at Einstein Hospital in Philadelphia 1Q 2023 Dr…

SFA Therapeutics CEO Ira Spector Profiled in PharmaVoice

PROFILE A biotech CEO’s favorite ‘F’ word At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the…

Applied Clinical Trials Podcast Interview with SFA CEO

PODCAST Treat Disease, Not the Symptoms In this podcast, Dr. Ira Spector discusses how his career journey has epitomized the ability…

Med Tech Gurus “Developing The Next Big Thing” Interviews SFA Therapeutics CEO Ira Spector

Med Tech Gurus Developing The Next Big Thing Ira Spector Co-Founder & CEO of SFA Therapeutics delivers a master class in innovation and…

SFA Therapeutics Founders Publish an Article Titled “Short‑chain fatty acids in cancer pathogenesis”

Abstract Cancer is a multi-step process that can be viewed as a cellular and immunological shift away from homeostasis in response…

SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis

JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) — SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results…

SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent

SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75 $4.5 Million Bridge Financing led by North South Ventures Composition…

Ben Franklin Healthcare Investments: 1.3 Million in Four Companies

Ben Franklin Healthcare Investments Invests $1.3 Million in Four Companies   Ben Franklin Healthcare Investments continues support of SFA Therapeutics with…

SFA Therapeutics Strengthens Management Team with Appointment of Chief Medical Officer

JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ — SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory…

Article by SFA Therapeutics Founders Featured in Drug Target Review

  In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches. The Promise…